Modern approaches to the diagnosis and treatment of small intestinal bacterial overgrowth syndrome

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Small intestinal bacterial overgrowth syndrome (SIBOS) is a clinical and microbiological syndrome characterized by changes in the abundance and composition of the small intestinal microbiota, gastrointestinal symptoms (bloating, abdominal pain, diarrhea, or constipation), malabsorption, and nutritional deficiency in severe cases. Modern diagnostics are based on an assessment of the clinical manifestations of the disease, consideration of risk factors, and laboratory results, such as a hydrogen-methane breath test and small intestinal aspirate culture. Treatment of SIBOS includes intestinal microbial decontamination, restoration of normal microflora, elimination of nutritional deficiencies, and correction of risk factors for this condition. This review systematizes modern algorithms for the diagnosis and treatment of small intestinal bacterial overgrowth syndromw (SIBOS), based on the principles of evidence-based medicine. It presents data on the role of probiotics and synbiotics in restoring the intestinal microbiome and preventing relapses of dysbiotic disorders.

About the authors

Olga A. Mubarakshina

Voronezh State Medical University named after N.N. Burdenko

Author for correspondence.
Email: mubarakshina@mail.ru
ORCID iD: 0000-0001-6799-6322

Cand. Sci. (Med.), Associate Professor, Department of Clinical Pharmacology

Russian Federation, Voronezh

Yulia M. Dronova

Voronezh State Medical University named after N.N. Burdenko

Email: y.dronova@yandex.ru
ORCID iD: 0000-0003-4513-091X

Cand. Sci. (Med.), Associate Professor, Department of Clinical Pharmacology

Russian Federation, Voronezh

Sergey Y. Chernov

Voronezh State Medical University named after N.N. Burdenko

Email: sergeych6868@mail.ru
ORCID iD: 0009-0002-8900-7745

Cand. Sci. (Med.), Associate Professor, Department of Clinical Pharmacology

Russian Federation, Voronezh

Olga A. Zhdanova

Voronezh State Medical University named after N.N. Burdenko

Email: olga.vr9@yandex.ru
ORCID iD: 0000-0002-3917-0395

Dr. Sci. (Med.), Associate Professor, Professor, Department of Clinical Pharmacology

Russian Federation, Voronezh

References

  1. Синдром избыточного бактериального роста в тонкой кишке: МКБ-10: К63.8: клинические рекомендации. Научное сообщество по содействию клиническому изучению микробиома человека, Российская гастроэнтерологическая ассоциация, Российское общество профилактики неинфекционных заболеваний. Москва. 2025. 42 с. - Текст: электронный. [Small intestinal bacterial overgrowth syndrome: ICD-10: K63.8: clinical guidelines. Scientific community for the promotion of clinical study of the human microbiome, Russian Gastroenterological Association, Russian Society for the Prevention of Non-communicable Diseases. Moscow. 2025. 42 p. - Text: electronic. (In Russ.)]. URL: https://mcrbm.com/files/getlinkedfile/48190/?download=false
  2. Алексеева О.С., Шаманина Я.Е., Штак К.П. и др. Современные аспекты диагностики и лечения синдрома избыточного бактериального роста. Вестник Санкт-Петербургского университета. Медицина. 2025;20(3):262–277. [Alekseeva O.S., Shamanina Ya.E., Shtak K.P. et al. Modern aspects of diagnosis and treatment of bacterial overgrowth syndrome. Vestnik of Saint Petersburg University. Medicine. 2025;20(3):262–277. (In Russ.)].
  3. Efremova I., Maslennikov R., Poluektova E., et al. Epidemiology of small intestinal bacterial overgrowth. World J Gastroenterol. 2023;29(22):3400–3421. http://dx.doi.org/10.3748/wjg.v29.i22.3400
  4. Ивашкин В.Т., Фомин В.В., Ткачева О.Н. и др. Синдром избыточного бактериального роста в практике врачей различных специальностей (Обзор литературы и резолюция Экспертного совета). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(2):14-34. [Ivashkin V.T., Fomin V.V., Tkacheva O.N., et al. Small Intestinal Bacterial Overgrowth in Various Specialties of Medical Practice (Literature Review and Expert Council Resolution). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(2):14-34. (In Russ.)]. https://doi.org/10.22416/1382-4376-2024-954
  5. Ивашкин В.Т., Маев И.В., Абдулганиева Д.И. и др. Практические рекомендации Научного сообщества по содействию клиническому изучению микробиома человека (НСОИМ) и Российской гастроэнтерологической ассоциации (РГА) по диагностике и лечению синдрома избыточного бактериального роста у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(3):68–85. [Ivashkin V.T., Maev I.V., Abdulganieva D.I., et al. Practical Recommendation of the Scientific community for human microbiome research (CHMR) and the Russian Gastroenterological Association (RGA) on Small Intestinal Bacterial Overgrowth in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(3):68–85. (In Russ.)]. https://doi.org/10.22416/1382-4376-2022-32-3-68-85
  6. Takakura W., Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome - An Update. Front. Psychiatry. 2020;(11):664. https://doi.org/10.3389/fpsyt.2020.00664
  7. Shah A., Morrison M., Burger D. et al. Systematic review with meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(6):624–35. https://doi.org/10.1111/apt.15133
  8. Rao S.S.C., Tan G., Abdulla H. et al. Does colectomy predispose to small intestinal bacterial (SIBO) and fungal overgrowth (SIFO)? Clin Transl Gastroenterol. 2018; 9(4): 146. https://doi.org/10.1038/s41424-018-0011-x
  9. Chander Roland B., Mullin G.E., Passi M., et al. A Prospective Evaluation of Ileocecal Valve Dysfunction and Intestinal Motility Derangements in Small Intestinal Bacterial Overgrowth. 2017 Dec;62(12):3525-3535. https://doi.org/10.1007/s10620-017-4726-4
  10. Su T., Lai S., Lee A. et al. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018;53(1):27–36. https://doi.org/10.1007/s00535-017-1371-9
  11. Esposito S., Biscarini A., Federici B. et al. Role of Small Intestinal Bacterial Overgrowth (SIBO) and Inflammation in Obese Children. Front Pediatr. 2020;8:369. https://doi.org/10.3389/fped.2020.00369
  12. Hegade V.S., Speight .R.A, Etherington R.E., Jones D.E. Novel bile acid therapeutics for the treatment of chronic liver diseases. Therap Adv Gastroenterol. 2016;9(3):376–91. https://doi.org/10.1177/1756283x16630712
  13. Lee A.A., Baker J.R., Wamsteker E.J. et al. Small Intestinal Bacterial Overgrowth Is Common in Chronic Pancreatitis and Associates With Diabetes, Chronic Pancreatitis Severity, Low Zinc Levels, and Opiate Use. Am J Gastroenterol. 2019;114(7):1163–71. https://doi.org/10.14309/ajg.0000000000000200
  14. Sorathia S.J., Chippa V., Rivas J.M. Small Intestinal Bacterial Overgrowth. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023; Jan-17. URL: https://www.ncbi.nlm.nih.gov/books/NBK546634/
  15. Montoro-Huguet M.A., Belloc B., Domínguez-Cajal M. Small and Large Intestine (I): Malabsorption of Nutrients. Nutrients. 2021;13(4):1254. https://doi.org/https://doi.org/10.3390/nu13041254
  16. Ricci J.E.R. Júnior, Chebli L.A., Ribeiro T.C.D.R. et al. Small-Intestinal Bacterial Overgrowth is Associated With Concurrent Intestinal Inflammation But Not With Systemic Inflammation in Crohn’s Disease Patients. J Clin Gastroenterol. 2018 Jul;52(6):530-536. https://doi.org/10.1097/mcg.0000000000000803
  17. Quigley E.M.M, Murray J.A., Pimentel M.Clinical Practice Update on Small Intestinal Bacterial Overgrowth : Expert Review Gastroenterol. 2020;159(4):1526-32. https://doi.org/10.1053/j.gastro.2020.06.090
  18. Ghosh G., Jesudian A.B. Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis. J Clin Exp Hepatol. 2019;9(2):257–67. https://doi.org/10.1016/j.jceh.2018.08.006
  19. Ивашкин В.Т., Медведев О.С., Полуэктова Е.А. и др. Прямые и косвенные методы изучения микробиоты человека. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(2):19-34. [Ivashkin V.T., Medvedev O.S., Poluektova E.A., Kudryavtseva A.V., Bakhtogarimov I.R., Karchevskaya A.E. Direct and Indirect Methods for Studying Human Gut Microbiota. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(2):19–34. (In Russ.)]. https://doi.org/10.22416/1382-4376-2022-32-2-19-34
  20. Rao S.S.C., Bhagatwala J. Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management. Clin Transl Gastroenterol. 2019;10(10):e00078. https://doi.org/10.14309/ctg.0000000000000078
  21. Hammer H.F., Fox M.R., Keller J. et al. European H2-CH4-breath test group. European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus. United European Gastroenterol J. 2022;10(1):15–40. https://doi.org/10.1002/ueg2.12133
  22. Rezaie A., Buresi M., Lembo A., et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017;112(5):775-84. https://doi.org/10.1038/ajg.2017.46
  23. Pimentel M., Saad R.J., Long M.D., Rao S.S.C. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115(2):165-78. https://doi.org/10.14309/ajg.0000000000000501
  24. Lim J., Rezaie A. Pros and Cons of Breath Testing for Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth. Gastroenterol Hepatol (N Y). 2023 Mar;19(3):140-146.
  25. Gillis J.C., Brogden R.N. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995 Mar;49(3):467-84. https://doi.org/10.2165/00003495-199549030-00009
  26. Кетова Г.Г., Шамина О.М., Миронов И.Л. Рифаксимин в терапии заболеваний желудочно- кишечного тракта: от истории создания до современных рекомендаций. Терапия. 2025;(5):153-65. [Ketova G.G., Shamina O.M., Mironov I.L. Rifaximin in the treatment of gastrointestinal diseases: from the history of creation to modern. Therapy. 2025;(5):153-65. (In Russ.)]. https://dx.doi.org/10.18565/therapy.2025.5.153-165
  27. Bianchera A., Nebuloni M., Colombo N., et al. Highly Polymorphic Materials and Dissolution Behaviour: The Peculiar Case of Rifaximin. Pharmaceutics. 2022 Dec 24;15(1):53. https://doi.org/10.3390/pharmaceutics15010053
  28. Blandizzi C., Viscomi G.C., Scarpignato C. Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers. Drug Des Devel Ther. 2014 Dec 16;9:1-11. https://doi.org/10.2147/DDDT.S72572
  29. Зырянов С.К., Байбулатова Е.А. Рифаксимин-альфа и другие кристаллические формы рифаксимина: есть ли отличия? Антибиотики и Химиотерапия. 2020;65(7-8):52-62. [Zyryanov S.K., Baibulatova E.A. Rifaximin-alpha and other crystalline forms of rifaximin: are there any differences? Antibiotics and Chemotherapy. 2020;65(7-8):52-62. (In Russ.)]. https://doi.org/10.37489/0235-2990-2020-65-7-8-52-62
  30. Клиническая фармакология: национальное руководство. Под ред. В.И. Петрова, Д.А. Сычева, А.Л. Хохлова. 2-е изд., перераб. и доп. Москва: ГЭОТАР-Медиа, 2024. 816 с. [Clinical Pharmacology: National Guidelines. Edited by V.I. Petrov, D.A. Sychev, A.L. Khokhlova. 2nd ed., revised and enlarged. Moscow: GEOTAR-Media, 2024. 816 p. (In Russ.)]. https://doi.org/10.33029/9704-8266-7-СP2-2024-1-816 / URL: https://medbase.ru/book/ISBN9785970482667.html (дата обращения / date of access: 23.03.2026).
  31. Low K., Hwang L., Hua J. et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test J Clin Gastroenterol. 2010;44(8):547-50. URL: https://pubmed.ncbi.nlm.nih.gov/19996983/
  32. Khurmatullina A.R., Andreev D.N., Kucheryavyy Yu.A. et al. The Duration of Proton Pump Inhibitor Therapy and the Risk of Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-Analysishttps: J Clin Med. 2025;14(13):4702. https://doi.org/10.3390/jcm14134702
  33. Goodman C., Keating G., Georgousopoulou E. et al. Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. BMJ Open. 2021; Aug 12;11(8):e043054. https://doi.org/10.1136/bmjopen-2020-043054
  34. Goldenberg J.Z., Yap C., Lytvyn L. et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017 Dec 19;12(12):CD006095. https://doi.org/10.1002/14651858.cd006095.pub4
  35. Swanson K.S., Gibson G.R., Hutkins R. et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020;17:687–701. https://doi.org/10.1038/s41575-020-0344-2
  36. Goodman C., Keating G., Georgousopoulou E., et al. Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. BMJ Open. 2021 Aug 12;11(8):e043054. https://doi.org/10.1136/bmjopen-2020-043054
  37. Goldenberg J.Z., Yap C., Lytvyn L., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017 Dec 19;12(12):CD006095. https://doi.org/10.1002/14651858.CD006095.pub4
  38. Ивашкин В.Т., Маев И.В., Абдулганиева Д.И. и др. Практические рекомендации Научного сообщества по содействию клиническому изучению микробиома человека (НСОИМ) и Российской гастроэнтерологической ассоциации (РГА) по применению пробиотиков, пребиотиков, синбиотиков и обогащенных ими функциональных пищевых продуктов для лечения и профилактики заболеваний гастроэнтерологического профиля у детей и взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(2):65-91. [Ivashkin V.T., Maev I.V., Abdulganieva D.I., et al. Practical Recommendations of Scientific Society for the Study of Human Microbiome and the Russian Gastroenterological Association on Use of Probiotics, Prebiotics, Synbiotics and Functional Foods in Treatment and Prevention of Gastroenterological Diseases in Children and Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(2):65-91. (In Russ.)]. https://doi.org/10.22416/1382-4376-2021-31-2-65-91
  39. Kashyap P., Moayyedi P., Quigley E.M.M., et al. Critical appraisal of the SIBO hypothesis and breath testing: A clinical practice update endorsed by the European society of neurogastroenterology and motility (ESNM) and the American neurogastroenterology and motility society (ANMS). Neurogastroenterology & Motility. 2024;36:e14817. https://doi.org/10.1111/nmo.14817

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 Bionika Media

License URL: https://journals.eco-vector.com/2073-4034/about/editorialPolicies